Baxter announces FDA approval of Advate with Baxject III reconstitution system Baxter International announced that the U.S. Food and Drug Administration has approved a new reconstitution system for ADVATE. ADVATE and the diluent come pre-packaged in the new BAXJECT III reconstitution system.
Baxter resumed with a Neutral from Overweight at Piper Jaffray Piper Jaffray analyst Brooks West downgraded Baxter (BAX) to Neutral after resuming coverage of the name. The company, post the spin of Baxalta (BXLT), "has a number of moving pieces that need to be addressed," West tells investors in a research note. He lowered his price target for shares to $39 from $90.